Evaluation of the Effects of Baricitinib in Acute Respiratory Distress Syndrome (ARDS) Patients
Phase 3
Recruiting
- Conditions
- Acute respiratory distress syndrome.Severe acute respiratory syndrome [SARS], unspecifiedU04.9
- Registration Number
- IRCT20231017059748N3
- Lead Sponsor
- Vice chancellor for Research,Tabriz University Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Adults with mild to moderate Acute Respiratory Distress Syndrome (ARDS) who require oxygen therapy (PaO2/FiO2 < 300 mmHg)
Patients who are capable of long-term supine position
Exclusion Criteria
Pregnancy
Age below 18 and above 80 years
concomitant diseases (infection/suppression of immune system, human immunodeficiency virus, liver, kidney and/acquired immunodeficiency syndrome)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method High-flow nasal oxygen therapy and noninvasive ventilation. Timepoint: Length of hospital stay. Method of measurement: observation.;Invasive mechanical ventilation. Timepoint: Length of hospital stay. Method of measurement: observation.
- Secondary Outcome Measures
Name Time Method O2 saturation. Timepoint: Twice a day (morning and evening) and while receiving non-invasive ventilation until the patient is hospitalized in the intensive care unit. Method of measurement: Pulse oximeter.;Duration of stay in intensive care unit. Timepoint: From the time of admission to the intensive care unit until the time of discharge or death. Method of measurement: Observation.;The number of days without a ventilator. Timepoint: Length of hospital stay. Method of measurement: Observation.;Duration of recovery. Timepoint: Length of hospital stay. Method of measurement: Observation.;Paient outcom. Timepoint: Length of hospital stay. Method of measurement: Observation.